Bausch Christoph Lawrence 4

What Happened Christoph Lawrence Bausch, Chief Operating Officer of SAB Biotherapeutics (SABS), received a grant of 1,800,000 derivative securities (options) on February 3, 2026. The Form 4 reports the acquisition as an award (transaction code A) with an acquisition price of $0.00 (i.e., a compensation grant rather than an open‑market purchase). The filing does not list a cash value or the option exercise (strike) price in the summary; see the full filing for the strike price if needed.

Key Details

• Transaction date: 2026-02-03; Form 4 filed 2026-02-05 (timely filing).
• Transaction type: Award/Grant of options (derivative) — 1,800,000 shares reported as acquired at $0.00.
• Vesting: Per footnote, these are options under the 2021 Omnibus Equity Incentive Plan. Vesting is over four years — 25% vests on the one‑year anniversary, remaining 75% vesting pro rata monthly over the next 36 months.
• Shares owned after transaction: Not specified in the provided summary (refer to the full Form 4 for the insider’s total holdings).
• Footnotes: F1 = options granted under the 2021 Omnibus Equity Incentive Plan; F2 = 4‑year vesting schedule detailed above.
• Filing timeliness: Filing appears timely (filed two days after the transaction date).

Context This was a compensation grant of stock options (a common form of executive compensation), not an open‑market purchase or sale. Such grants do not by themselves indicate immediate buying or selling of shares — value is realized only if and when options are exercised and shares are sold. Retail investors should consult the full Form 4 for the option strike price and total post‑grant holdings to assess potential dilution and incentive alignment.